The Cooper Companies, Inc.

DB:CP60 Stock Report

Market Cap: €18.9b

Cooper Companies Valuation

Is CP60 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CP60 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CP60 (€93.65) is trading below our estimate of fair value (€169.07)

Significantly Below Fair Value: CP60 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CP60?

Key metric: As CP60 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CP60. This is calculated by dividing CP60's market cap by their current earnings.
What is CP60's PE Ratio?
PE Ratio55.2x
EarningsUS$359.30m
Market CapUS$19.89b

Price to Earnings Ratio vs Peers

How does CP60's PE Ratio compare to its peers?

The above table shows the PE ratio for CP60 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.3x
PHH2 Paul Hartmann
12xn/a€710.3m
SHL Siemens Healthineers
28.8x14.2%€56.0b
AFX Carl Zeiss Meditec
25.7x16.3%€5.2b
FME Fresenius Medical Care
18.6x19.3%€12.3b
CP60 Cooper Companies
55.2x23.0%€19.9b

Price-To-Earnings vs Peers: CP60 is expensive based on its Price-To-Earnings Ratio (55.2x) compared to the peer average (21.3x).

Price to Earnings Ratio vs Industry

How does CP60's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CP60 55.2xIndustry Avg. 29.7xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CP60 is expensive based on its Price-To-Earnings Ratio (55.2x) compared to the European Medical Equipment industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is CP60's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CP60 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio55.2x
Fair PE Ratio33x

Price-To-Earnings vs Fair Ratio: CP60 is expensive based on its Price-To-Earnings Ratio (55.2x) compared to the estimated Fair Price-To-Earnings Ratio (33x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CP60 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€93.65
€108.72
+16.1%
9.2%€123.66€87.62n/a14
Nov ’25€96.10
€105.69
+10.0%
9.2%€120.21€85.18n/a14
Oct ’25€98.65
€101.66
+3.0%
8.9%€116.43€82.50n/a14
Sep ’25€95.00
€103.00
+8.4%
8.0%€112.86€85.78n/a13
Aug ’25€85.85
€102.39
+19.3%
7.9%€114.83€87.27n/a13
Jul ’25€80.80
€102.38
+26.7%
8.6%€116.64€88.64n/a14
Jun ’25€84.05
€99.70
+18.6%
10.0%€115.23€79.51n/a15
May ’25€84.40
€99.59
+18.0%
9.6%€115.38€79.61n/a16
Apr ’25€93.80
€98.85
+5.4%
9.5%€115.05€79.38n/a16
Mar ’25€91.00
€94.87
+4.3%
9.7%€107.04€77.79n/a16
Feb ’25€86.13
€90.02
+4.5%
8.2%€101.20€77.51n/a16
Jan ’25€85.63
€87.47
+2.2%
8.2%€97.37€76.31n/a16
Dec ’24€76.88
€89.41
+16.3%
7.6%€97.98€78.15n/a15
Nov ’24€73.25
€92.54
+26.3%
7.6%€101.25€80.77€96.1015
Oct ’24€75.25
€95.22
+26.5%
7.6%€104.15€81.66€98.6514
Sep ’24€85.25
€93.91
+10.2%
7.3%€102.11€80.07€95.0014
Aug ’24€88.88
€89.27
+0.4%
8.3%€97.83€72.26€85.8514
Jul ’24€87.13
€91.16
+4.6%
7.8%€98.72€74.44€80.8014
Jun ’24€86.75
€90.55
+4.4%
9.2%€99.91€74.35€84.0513
May ’24€85.50
€85.20
-0.4%
8.0%€98.00€72.93€84.4012
Apr ’24€84.05
€81.78
-2.7%
8.5%€89.94€64.58€93.8012
Mar ’24€76.83
€79.94
+4.0%
9.6%€88.54€64.39€91.0012
Feb ’24€79.75
€79.94
+0.2%
9.6%€88.54€64.39€86.1312
Jan ’24€77.90
€80.40
+3.2%
8.4%€88.46€66.05€85.6312
Dec ’23€75.38
€81.03
+7.5%
8.5%€88.78€67.19€76.8810
Nov ’23€68.95
€86.06
+24.8%
9.2%€96.56€72.10€73.2510

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

CVS Health

US$69.3b

Provides health solutions in the United States.

CVS

US$50.67

7D

-4.0%

1Y

-19.2%

Shandong Weigao Group Medical Polymer

HK$20.4b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-9.5%

1Y

-41.3%

Fagron

€1.4b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.54

7D

-1.2%

1Y

9.3%